On Friday, Shares of Yum! Brands, Inc. (NYSE:YUM), gained 0.36% to $78.60.
Yum! Brands, declared the appointment of Brian Cornell to its Board of Directors. Cornell is the Chairman and Chief Executive Officer of Target Corporation (TGT). The appointment is effective right away.
“Brian will make an outstanding addition to the Yum! Brands Board of Directors,” said David Novak, Executive Chairman, Yum! Brands. “Brian is a seasoned retail and consumer products veteran. He brings a wealth of knowledge and best practices to YUM leading one of the largest and most innovative retail companies in the world.”
“We are thrilled to welcome Brian to the Yum! Brands Board of Directors,” said Greg Creed, Chief Executive Officer, Yum! Brands. “As we continue to build three iconic global brands that people trust and champion through insight-driven marketing, breakthrough product innovation and digital leadership, Brian’s expertise will complement our efforts to strengthen and grow our brands around the world and deliver strong performance for our shareholders over the long term.”
YUM! Brands, Inc., together with its auxiliaries, operates quick service restaurants. It operates in five segments: YUM China, YUM India, the KFC Division, the Pizza Hut Division, and the Taco Bell Division.
Shares of PDL BioPharma Inc (NASDAQ:PDLI), declined - 4.22% to $5.22, during its last trading session.
PDL BioPharma, declared that PDL has received about $21.4 million in connection with the termination of PDL’s structured financing agreement with Avinger, Inc. (AVGR), which comprised repayment of the full principal amount outstanding of $20.6 million in addition to accrued interest and a prepayment fee. In April 2013, PDL reached a loan and royalty agreement with Avinger in which PDL agreed to provide them with up to $40 million of financing and in turn would receive interest on the principal amount outstanding in addition to a low single digit royalty on Avinger’s revenues from the sale of their suite of products. PDL only funded $20 million of the committed amount; however under terms of the agreement, PDL will continue to receive a reduced royalty of 0.9% on Avinger’s net revenues from the prepayment date through 2018, subject to minimum quarterly payments.
“We were happy to have the opportunity to provide financial support to Avinger while they advanced their pipeline of products through clinical development,” stated John P. McLaughlin, president and chief executive officer of PDL. “To date, we have offered 15 different companies or institutions with non-dilutive capital and have committed over one billion dollars in the process. We are continuously assessing top quality income generating assets to add to our growing portfolio.”
PDL BioPharma, Inc. manages a portfolio of patents and royalty assets in the United States and Europe. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases.
At the end of Friday’s trade, Shares of CA, Inc. (NASDAQ:CA), lost -0.55% to $27.36.
Working Mother magazine, named CA Technologies (CA) as one of the 2015 Working Mother 100 Best Companies for its commitment to progressive workplace programs, counting advancement of women, flexibility, child care and paid parental leave. The 100 Best Companies are featured in the October/November issue of Working Mother and on workingmother.com.
“Once again, CA is honored to be recognized by Working Mother as one of their 100 Best Companies,” said Beth Conway, vice president, Human Resources, CA Technologies. “We support our working parents in achieving work-life integration through our progressive workplace programs and promote a corporate culture that fosters empowerment, growth and innovation. By delivering comprehensive programs and benefits to meet the needs of our employees and their families, we can assist drive a happier and more loyal employee base – which drives success for everyone.”
CA, Inc. provides information technology (IT) administration software and solutions that assist organizations plan, develop, manage, and secure applications and IT infrastructure in the United States and internationally.
Finally, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), ended its last trade with -13.51% loss, and closed at $2.24.
Eisai Inc. and Arena Pharmaceuticals, declared that lorcaserin HCl data will be presented at the following medical meetings:
- 2015 Annual Meeting of the American College of Clinical Pharmacology, taking place September 27-29, 2015, in San Francisco, California
Pharmacokinetics and Safety of Lorcaserin in Adolescents With Obesity
Poster Number: 81
This study evaluated the pharmacokinetic properties, safety and tolerability of a single 10 mg dose of lorcaserin in obese adolescents.
- American Society of Bariatric Physicians meeting: Overcoming Obesity 2015, taking place September 30-October 4, 2015, in Washington, D.C.
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight administration in adults.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
